Prevention & care
Female infertility: ovulation, tubes, ovarian reserve and treatment outcomes
On this page
Female-factor infertility concerns problems involving ovulation, eggs or reproductive anatomy that contribute to difficulty achieving pregnancy. Several factors may coexist. The label does not imply that a partner’s sperm is irrelevant, and it is not a judgment about a person’s health choices. Identifying the mechanism matters because different mechanisms call for different investigations and treatments.[1]
Ovulatory, tubal and uterine problems are different categories
Ovulatory disorders involve an egg not being released regularly. Hormonal conditions, including PCOS, thyroid disease or primary ovarian insufficiency, can contribute. Tubal problems can prevent sperm and egg meeting; scarring after pelvic infection is one possible cause. Uterine abnormalities may affect implantation or pregnancy. Endometriosis can also contribute. A diagnosis such as fibroids does not establish infertility in every person; location, size and clinical context matter. Multiple factors and unexplained cases remain possible.[1]
Ovarian reserve measures quantity rather than a complete fertility forecast
Ovarian reserve refers to the remaining egg or follicle pool. AMH is a blood marker produced by cells around developing eggs. ACOG distinguishes its use in ovarian-reserve assessment and stimulation planning from unsupported general predictions of natural fertility. Egg quantity, age-related reproductive potential and the chance of pregnancy are related but different concepts. A reassuring AMH result cannot guarantee fertility; a low value cannot alone establish that pregnancy is impossible.[2]
IVF, insemination and ovulation medicines are not synonyms
In IVF, eggs are retrieved and combined with sperm in a laboratory; an embryo may then be transferred to a uterus. CDC defines assisted reproductive technology as procedures handling eggs or embryos. Intrauterine insemination places prepared sperm into the uterus and is outside that CDC ART definition when only sperm are handled. Ovulation medicines without planned egg retrieval are also outside it. “Fertility treatment” is the broader term. This classification helps explain why a clinic’s IVF success figure cannot be applied to every intervention.[4]
Check the outcome and what is being counted
A clinic’s percentage needs an outcome and a denominator: the group or units being counted. The UK Competition and Markets Authority explains why changing either can change a reported success rate without changing the underlying treatment results.[8]
| Measure | What it counts |
|---|---|
| Live birth per cycle started | All started treatment cycles, including those that do not reach embryo transfer.[8] |
| Live birth per transfer procedure | Transfer procedures; one procedure may involve more than one embryo.[8] |
| Births per embryo transferred | Individual embryos transferred, rather than transfer procedures.[8] |
| Pregnancy versus live birth | Earlier pregnancy outcomes and a live birth are different endpoints.[8] |
A cumulative course and a single transfer are different views
Cumulative statistics combine outcomes from embryo transfers belonging to the same treatment cycle. The Human Fertilisation and Embryology Authority (HFEA) says its detailed tables are not cumulative and directs readers to the main profile for that view. Ask which fresh or later frozen transfers and follow-up period a quoted rate includes. The current main tool describes both births per egg collection procedure and births per embryo transferred.[9]
Patient age, infertility circumstances and the number treated affect comparisons. HFEA’s reliability ranges express uncertainty. A clinic rate describes past results rather than a personal prediction. Consider the wider service rather than only the highest percentage.[9]
Evidence & uncertainty
ASRM recommends evaluation after 12 months of trying for women under 35 and after six months at 35 or older unless earlier assessment is indicated. Known conditions, irregular cycles or age over 40 can justify earlier assessment. These are US clinical timing recommendations, not instructions to delay care despite a concerning history.[5]
Selected-source overview · Independent review pendingPublished questions
Must everyone wait a year before seeking evaluation?
Selected-source overview · Independent review pending. Read the evidence context.
No. ASRM gives shorter timelines with age and recommends prompt evaluation when a condition known to impair fertility is already present.[5]
Evidence behind this answer
- Fertility evaluation of infertile women: a committee opinion (2021)
professional or agency guidance · 2021
Original official page; selected relevant passages inspected · Initial timing; earlier-indication list; donor-sperm and parallel-partner evaluation; conclusions
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does having fibroids mean I am infertile?
Selected-source overview · Independent review pending. Read the evidence context.
Not necessarily. NICHD notes that most women with fibroids can become pregnant; their size, location and effects differ.[1]
Evidence behind this answer
- What are some possible causes of female infertility?
official public health explanation · Date not stated
Original official page; selected relevant passages inspected · Failure to Ovulate; Structural Problems; Infections; PCOS and primary ovarian insufficiency
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is AMH a pass-or-fail fertility test?
Selected-source overview · Independent review pending. Read the evidence context.
No. It informs ovarian-reserve and stimulation-response assessment but does not independently settle whether natural conception or live birth will occur.[2]
Evidence behind this answer
- ACOG Committee Opinion No. 773: The Use of Antimüllerian Hormone in Women Not Seeking Fertility Care
professional committee opinion indexed abstract · 2019
Indexed official committee-opinion abstract inspected; full ACOG page returned a payment-required error · Indexed original committee-opinion abstract: AMH production, ovarian-reserve context and unsupported general fertility counseling
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Are insemination and IVF the same procedure?
Selected-source overview · Independent review pending. Read the evidence context.
No. Insemination handles sperm; IVF involves retrieving eggs and creating embryos outside the body. CDC classifies their reporting scope differently.[4]
Evidence behind this answer
- About ART
official public health explanation · 2024
Original official page; selected relevant passages inspected · ART definition and explicit exclusions for sperm-only insemination and ovulation medicines
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can an ovulation medicine necessarily correct blocked tubes?
Selected-source overview · Independent review pending. Read the evidence context.
No. Stimulating egg release addresses a different mechanism. NICHD distinguishes ovulatory treatment from approaches for tubal damage.[6]
Evidence behind this answer
- Fertility Treatments for Females
official public health explanation · Date not stated
Official educational page selected mechanism and treatment-context passages inspected; no product dosing instructions or historical blanket success estimate adopted · Treatment depends on underlying cause; ovulation versus tubal damage; monitoring context
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does the PCOS trial guarantee a live birth with letrozole?
Selected-source overview · Independent review pending. Read the evidence context.
No. Most participants did not have a live birth during the study’s treatment course. The comparison describes group outcomes within a specific population.[7]
Evidence behind this answer
- New treatment increases pregnancy rate for women with infertility disorder
original trial network report · 2014
Original trial-network/funder report inspected; full trial article not independently appraised · July 9 2014 original network-trial announcement; 750 participants; live-birth denominators and unresolved rare outcomes
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Why can a rate per transfer look higher than a rate per started cycle?
Selected-source overview · Independent review pending. Read the evidence context.
Cycles that never reach transfer are absent from the transfer denominator. A higher percentage can reflect counting a later stage rather than better treatment. Compare the same outcome and counting unit.[8]
Evidence behind this answer
- Fertility treatment: a guide to your consumer rights
official consumer information · 2021
Complete relevant original success-rate explanation read. Definitions and comparison task only; no individual legal determination, numerical clinic ranking, legal deadline or claim about current HFEA headline preferences adopted. · Original Success rates / Understanding clinics’ success rate measures, lines 161–191; definitions of started cycles, transfer procedures, individual embryos and pregnancy outcomes
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can I compare one clinic’s pregnancy percentage with another clinic’s live-birth percentage?
Selected-source overview · Independent review pending. Read the evidence context.
They measure different outcomes. Ask whether the endpoint is a positive test, a clinical pregnancy or a live birth before comparing percentages.[8]
Evidence behind this answer
- Fertility treatment: a guide to your consumer rights
official consumer information · 2021
Complete relevant original success-rate explanation read. Definitions and comparison task only; no individual legal determination, numerical clinic ranking, legal deadline or claim about current HFEA headline preferences adopted. · Original Success rates / Understanding clinics’ success rate measures, lines 161–191; definitions of started cycles, transfer procedures, individual embryos and pregnancy outcomes
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does a per-transfer success rate include every later frozen transfer from the same treatment cycle?
Selected-source overview · Independent review pending. Read the evidence context.
Not necessarily. HFEA distinguishes its non-cumulative detailed statistics from a cumulative view. Ask which transfers and time period are included before treating the number as a whole-course result.[9]
Evidence behind this answer
- Choose a fertility clinic: success measures, comparison limits and cumulative-statistics explanation
official regulator tool methodological guidance · Date not stated
Complete relevant current tool-help body and linked statistics-help statement read. The same tool’s explanatory pages are conservatively one work, not independent evidence. No individual clinic result, ranking or personal probability adopted. · Current main tool help: What data, different success rates, comparison and reliability ranges, lines 84–111; linked detailed-statistics page non-cumulative explanation, lines 61–66
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does the clinic with the highest percentage necessarily offer my best chance?
Selected-source overview · Independent review pending. Read the evidence context.
No. Patient mix, treatment circumstances and statistical uncertainty affect comparisons. HFEA advises considering the wider service; an overall clinic rate cannot predict your individual outcome.[9]
Evidence behind this answer
- Choose a fertility clinic: success measures, comparison limits and cumulative-statistics explanation
official regulator tool methodological guidance · Date not stated
Complete relevant current tool-help body and linked statistics-help statement read. The same tool’s explanatory pages are conservatively one work, not independent evidence. No individual clinic result, ranking or personal probability adopted. · Current main tool help: What data, different success rates, comparison and reliability ranges, lines 84–111; linked detailed-statistics page non-cumulative explanation, lines 61–66
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
A workup connects the history to specific tests
ASRM describes assessment of ovulation, the reproductive tract and sperm contribution where applicable. Evaluation of both contributing partners can proceed together. Tests for tubal openness address a different question from ovarian-reserve tests, and a broad hormone panel does not replace anatomical assessment. Investigations should follow relevant history rather than treating every available test as a necessary package. A person using donor sperm may need an assessment tailored to their circumstances; needing assistance to build a family does not automatically identify an ovarian disease.[5]
Treatment must address the cause and its tradeoffs
NICHD explains that treatments aimed at stimulating ovulation are more relevant to ovulatory problems than to blocked fallopian tubes. Treating an underlying hormonal disorder can sometimes improve fertility. Medication, surgery and assisted reproduction are different pathways with different monitoring burdens and risks. A response such as ovulation is an intermediate outcome, not the same as live birth. Treatment choice also depends on age, previous pregnancies, infertility duration and sperm factors, so a generic “success rate” cannot select a treatment for an individual.[6]
A PCOS trial shows why absolute outcomes and eligibility matter
An NIH-supported randomized trial enrolled 750 infertile women aged 18–40 with PCOS and compared letrozole with clomiphene across up to five treatment cycles. Live birth occurred in 27.5% versus 19.1% of assigned participants: an absolute difference of 8.4 percentage points, approximately eight additional births per 100 treated in that study. This is not an 8.4% relative change or a promise for one cycle. The trial population and protocol matter; results cannot establish the best therapy for tubal infertility or every unexplained case. Rare adverse outcomes required further study.[7]
A biomarker can help planning while leaving prognosis uncertain
ASRM notes that reserve tests predict egg yield more strongly than live birth. Age, sperm, embryos and procedures still matter. An extremely low AMH value should not alone exclude access to IVF. This cautions against treating one measurement as a definitive verdict, without claiming that reserve tests lack value or that success is assured.[3]
References
- What are some possible causes of female infertility?
Official public health explanation
US NICHD · Content/publication date: not stated
Accessed: 2026-10-13 UTC · Original official page; selected relevant passages inspected
Cited sections: Failure to Ovulate; Structural Problems; Infections; PCOS and primary ovarian insufficiency - ACOG Committee Opinion No. 773: The Use of Antimüllerian Hormone in Women Not Seeking Fertility Care
Professional committee opinion indexed abstract
ACOG / PubMed · Content/publication date: 2019
Accessed: 2026-10-13 UTC · Indexed official committee-opinion abstract inspected; full ACOG page returned a payment-required error
Cited sections: Indexed original committee-opinion abstract: AMH production, ovarian-reserve context and unsupported general fertility counseling - Testing and interpreting measures of ovarian reserve: a committee opinion (2020)
Professional or agency guidance
ASRM · Content/publication date: 2020
Accessed: 2026-10-13 UTC · Original official page; selected relevant passages inspected
Cited sections: Definitions; reproductive-potential predictions; stimulation response; low-AMH access warning - About ART
Official public health explanation
US CDC · Content/publication date: 2024
Accessed: 2026-10-13 UTC · Original official page; selected relevant passages inspected
Cited sections: ART definition and explicit exclusions for sperm-only insemination and ovulation medicines - Fertility evaluation of infertile women: a committee opinion (2021)
Professional or agency guidance
ASRM · Content/publication date: 2021
Accessed: 2026-10-13 UTC · Original official page; selected relevant passages inspected
Cited sections: Initial timing; earlier-indication list; donor-sperm and parallel-partner evaluation; conclusions - Fertility Treatments for Females
Official public health explanation
US NICHD · Content/publication date: not stated
Accessed: 2026-10-13 UTC · Official educational page selected mechanism and treatment-context passages inspected; no product dosing instructions or historical blanket success estimate adopted
Cited sections: Treatment depends on underlying cause; ovulation versus tubal damage; monitoring context - New treatment increases pregnancy rate for women with infertility disorder
Original trial network report
US NICHD / Reproductive Medicine Network · Content/publication date: 2014
Accessed: 2026-10-13 UTC · Original trial-network/funder report inspected; full trial article not independently appraised
Cited sections: July 9 2014 original network-trial announcement; 750 participants; live-birth denominators and unresolved rare outcomes - Fertility treatment: a guide to your consumer rights
Official consumer information
UK Competition and Markets Authority · Content/publication date: 2021
Accessed: 2026-10-20 UTC · Complete relevant original success-rate explanation read. Definitions and comparison task only; no individual legal determination, numerical clinic ranking, legal deadline or claim about current HFEA headline preferences adopted.
Cited sections: Original Success rates / Understanding clinics’ success rate measures, lines 161–191; definitions of started cycles, transfer procedures, individual embryos and pregnancy outcomes - Choose a fertility clinic: success measures, comparison limits and cumulative-statistics explanation
Official regulator tool methodological guidance
Human Fertilisation and Embryology Authority · Content/publication date: not stated
Accessed: 2026-10-20 UTC · Complete relevant current tool-help body and linked statistics-help statement read. The same tool’s explanatory pages are conservatively one work, not independent evidence. No individual clinic result, ranking or personal probability adopted.
Cited sections: Current main tool help: What data, different success rates, comparison and reliability ranges, lines 84–111; linked detailed-statistics page non-cumulative explanation, lines 61–66
Scope & review
- Population
- General readers; source-specific populations and eligibility are distinguished
- Exposure or intervention
- Female infertility
- Comparison
- Source-specific comparisons; no individual prescription or universal ranking
- Outcomes
- Definitions, subtypes, interpretation, practical context and uncertainty
- Timeframe
- Publication years and source update dates are recorded where established; sources retrieved 2026-10-13 (UTC)
- Jurisdiction
- US clinical context unless an international source is explicitly identified; access and local requirements differ
Selected-source educational explanation with source-specific limitations. No exhaustive search, independent systematic synthesis or qualified medical review.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-13 UTC: Added a selected-source educational explanation in edition 4.1; independent medical review remains pending.
- 2026-10-20 UTC: Depth15 additive practical-scope expansion after full old/neighbor body audit and selected original-source access; all old section, FAQ and source objects preserved. Qualified review remains pending.
What this article still leaves open
- These selected sources do not resolve every individual treatment choice or subgroup outcome.
- Independent medical review and an exhaustive evidence synthesis have not been completed.
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.